mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000

View company profile
Current Jobs

Health Policy Manager
Location: Nationwide

Oncology Hospital Specialist
Location: South and South West of England

Boehringer Ingelheim drug Micardis receives positive recommendation

Posted on 26/10/2009 in Pharmaceutical Company Product News

Boehringer Ingelheim has revealed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency has issued a positive opinion for the approval of Micardis (telmisartan) for the reduction of cardiovascular (CV) morbidity.

This applies to patients suffering from either manifest atherothrombotic cardiovascular disease or type 2 diabetes mellitus with documented target organ damage.

According to the firm, Micardis could offer a much-needed alternative to ACE inhibitors in the treatment of patients with high CV risk.

"We are delighted to receive this positive opinion from the CHMP. This is an important development that will help physicians ensure that patients receive appropriate treatment tailored to their individual needs," explained Professor Klaus Dugi, corporate vice-president of medical affairs at Boehringer Ingelheim.

This news comes after the Food and Drug Administration approved Micardis for use in patients at high risk of cardiovascular incidents.

Other news stories from 26/10/2009

Read more in the Zenopa News Archive

How this news is generated

Claire
Account Manager
for this opportunity

01494 818 025
(Mon to Fri 0830 to 1800 hours)
claire@zenopa.com

Latest News

Boehringer Ingelheim publishes dabigatran etexilate trial data

Boehringer Ingelheim to acquire SSP

Boehringer Ingelheim piglet castration product approved in EU

Boehringer Ingelheim to collaborate with Priaxon

Boehringer Ingelheim begins ovarian cancer trial

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use